Clinical Trials Browser

Active not recruiting × INDUSTRY × sotorasib × Clear all

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 1 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT05198934 2026-02-06

CodeBreak300

Phase 3 Active not recruiting

160 enrolled 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT06497556 2026-01-20

Krascendo 1

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05074810 2026-01-12

RAMP203

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT04303780 2025-10-14

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Phase 3 Active not recruiting

345 enrolled 11 charts

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

NCT04892017 2025-10-10

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04380753 2025-07-23

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Phase 1 Active not recruiting

12 enrolled 12 charts

Other solid neoplasm

Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation